| Released | Contributor | Author | Title | Pages | Price |
| 30-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Industry Report for DRUGS | 18 |
$49 |
| 30-Nov-2009 | Reuters Investment Profile |
N/A
| SeraCare Life Sciences Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. | 12 |
$20 |
| 30-Nov-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Biotechnology & Genetics Industry Market Research and Competitive Analysis 2010 | 569 |
$299 |
| 30-Nov-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Biotech & Genetics Industry Trends, Statistics & Analysis 2010 (Summary) | 71 |
$199 |
| 29-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Seracare Life Sci has a current Overall Rating of B (Positive). | 7 |
$25 |
| 29-Nov-2009 | Wright Reports |
N/A
| Wright Investors Service Comprehensive Report for SeraCare Life Sciences, Inc. | 42 |
$65 |
| 28-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Drug Intelligence Monitor: overall outlook NEUTRAL - 25 new Leaders; 25 new Laggards. | 65 |
$20 |
| 28-Nov-2009 | TheStreet.com Ratings |
N/A
| TheStreet.com Ratings Stock Report For: SERACARE LIFE SCIENCES INC | 5 |
$25 |
| 27-Nov-2009 | Pechala's Reports | Lubomir Pechala | SERACARE LIFE SCIENCES INC (SRLS=US) 2-weeks forecast | 1 |
$10 |
| 27-Nov-2009 | Pechala's Reports | Frantisek Pechala | SERACARE LIFE SCIENCES INC (SRLS=US) 12-months forecast | 1 |
$15 |
0.34% Nasdaq 0.00%
Research Reports
